City & Corporate: FD wins major pharma work

Hikma awards FD retained account after competitive four-way pitch.

FD has taken one of the largest healthcare firms listed on the London Stock Exchange from City rival Brunswick.

Hikma Pharmaceuticals, the fourth-largest Londonlisted firm in the sector, with a market cap of £1.3bn, has handed its retained financial and investor relations account to FD following a competitive pitch.

The FTSE 250 firm is based in Jordan and is listed on the NASDAQ Dubai exchange.

Previous incumbent Brunswick is understood to have repitched for the brief, alongside M:Communications and Capital MS&L - all agencies with a significant footprint in the Middle East.

Hikma operates principally in the Middle East and North Africa (MENA), and has built market-leading positions in these emerging markets, helping it become one of the few major international pharmaceutical firms posting strong growth in recent times.

Ben Atwell, an MD in the agency's life science team in London, said: 'Hikma is well established as one of the market leaders in its key MENA markets, as well as having a growing presence in the US and other parts of the world.'

Industry analysts suggest as much as 70 per cent of growth in the sector over the next five years will be driven by emerging markets.

Hikma is targeting double-digit annual growth and has already seen its UK share price rise by about 65 per cent in the past year.

FD will support this growth by managing its financial and investor comms both globally and regionally.

Atwell and fellow life sciences MDs Julia Phillips and Jonathan Birt will lead the account from the UK, supported by John Hobday, head of FD's UEA office, and Tala Abu Taha from FD's affiliate in Jordan, VARCC Communications.

FD's life sciences division has concentrated on growth internationally in recent times, expanding out of its traditional UK client list to pick up clients in further emerging markets such as Connexios in India.

Emerging markets are increasingly becoming a focus for multinational pharma giants. GlaxoSmithKline has bought firms in Argentina and South Korea, plus a stake in South Africa's Aspen Pharmacare in the past year, while Sanofi-Aventis has made acquisitions in Central and Eastern European, Brazil and Mexico.

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

John Lewis to tell brand story with "tasteful" 150th anniversary celebrations

John Lewis to tell brand story with "tasteful" 150th anniversary celebrations

Department store John Lewis is to use its 150th anniversary this year to talk about its history, which "not enough people know about", according to director of communications Peter Cross.

Labour hires Obama election strategist David Axelrod to fight General Election

Labour hires Obama election strategist David Axelrod to fight General Election

The man who helped Barack Obama win the 2008 and 2012 US presidential elections is to work for Labour along with members of his team.

Sky adds Fever PR to its roster after splitting with Cake

Sky adds Fever PR to its roster after splitting with Cake

Pay-TV giant Sky has added Fever PR to its agency line-up for a wide-ranging brief covering products and services.

Max Clifford trial jury to continue deliberations after Easter break

Max Clifford trial jury to continue deliberations after Easter break

The jury in the trial of celebrity publicist Max Clifford has been sent home for Easter and will reconvene on Tuesday for further deliberations about its verdicts on 11 charges of indecent assault.

Home Office brings in Munro & Forster to campaign against FGM

Home Office brings in Munro & Forster to campaign against FGM

The Home Office has tasked Munro & Forster (M&F) with supporting its campaign to eradicate female genital mutilation (FGM) as part of a wider retained brief.